Momelotinib Dihydrochloride Patent Expiration
Momelotinib Dihydrochloride is used for treating intermediate or high-risk myelofibrosis. It was first introduced by Glaxosmithkline Llc
Momelotinib Dihydrochloride Patents
Given below is the list of patents protecting Momelotinib Dihydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ojjaara | US11963962 | Platelet count-agnostic methods of treating myelofibrosis | Dec 02, 2040 | Glaxosmithkline |
| Ojjaara | US9809559 | (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide | Jun 11, 2035 | Glaxosmithkline |
| Ojjaara | USRE48285 | N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide | Jun 11, 2035 | Glaxosmithkline |
| Ojjaara | US8486941 | Phenyl amino pyrimidine compounds and uses thereof | Jan 03, 2030 | Glaxosmithkline |
Momelotinib Dihydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List